Foreskin as a source of immunotherapeutic mesenchymal stromal cells

Immunotherapy

Volumn 9, Issue 2, 2017, Pages 207-217

  Najar, Mehdi ^a   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

cell therapy; foreskin; immunobiology; mesenchymal stromal cells

Indexed keywords

CD34 ANTIGEN; CD40 ANTIGEN; CELL ADHESION MOLECULE; ENDOGLIN; HLA DR ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; PROGRAMMED DEATH 1 LIGAND 1; SCATTER FACTOR; THY 1 ANTIGEN; TOLL LIKE RECEPTOR;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL ISOLATION; CELL PLASTICITY; CYTOKINE RELEASE; GENE EXPRESSION; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; NONHUMAN; PLURIPOTENT STEM CELL; PREPUCE; REVIEW; STEM CELL CULTURE; STEM CELL SELF-RENEWAL; T LYMPHOCYTE ACTIVATION; TISSUE REGENERATION; ANIMAL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; PHYSIOLOGY; PROCEDURES;

ANIMALS; CELL DIFFERENTIATION; FORESKIN; HUMANS; IMMUNOTHERAPY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 85011028442     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0093     Document Type: Review

References (112)

1. Elahi KC, Klein G, Avci-Adali M, Sievert KD, MacNeil S, Aicher WK. Human mesenchymal stromal cells from different sources diverge in their expression of cell surface proteins and display distinct differentiation patterns. Stem Cells Int. 2016, 5646384 (2016).
2. Ferretti C, Mattioli-Belmonte M. Periosteum derived stem cells for regenerative medicine proposals: boosting current knowledge. World J. Stem Cells. 6(3), 266-277 (2014).
3. Ferretti C, Vozzi G, Falconi M, et al. Role of IGF1 and IGF1/VEGF on human mesenchymal stromal cells in bone healing: two sources and two fates. Tissue Eng. Part A. 20(17-18), 2473-2482 (2014).
4. Najar M, Raicevic G, Fayyad-Kazan H, et al. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev. 8(4), 1188-98 (2012).
5. Rada T, Reis RL, Gomes ME. Adipose tissue-derived stem cells and their application in bone and cartilage tissue engineering. Tissue Eng. Part B Rev. 15(2), 113-125 (2009).
6. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Whartons jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int. J. Mol. Sci. 14(6), 11692-11712 (2013).
7. Bongso A, Fong CY. The therapeutic potential, challenges and future clinical directions of stem cells from the Whartons jelly of the human umbilical cord. Stem Cell Rev. 9(2), 226-240 (2013).
8. Blanpain C, Fuchs E. Epidermal stem cells of the skin. Annu. Rev. Cell Dev. Biol. 22, 339-373 (2006).
9. Fernandes KJ, McKenzie IA, Mill P, et al. A dermal niche for multipotent adult skin-derived precursor cells. Nat. Cell Biol. 6(11), 1082-1093 (2004). important source of cell precursors
10. Limbourg A, Schnabel S, Lozanovski VJ, et al. Genetic reporter analysis reveals an expandable reservoir of OCT4+ cells in adult skin. Cell Regen. (Lond). 3(1), 9 (2014).
11. Ashley F. Foreskins as skin grafts. Ann. Surg. 106(2), 252-256 (1937).
12. Zaroo MI, Sheikh BA, Wani AH, et al. Use of preputial skin for coverage of post-burn contractures of fingers in children. Indian J. Plast. Surg. 44(1), 68-71 (2011).
13. Vishnubalaji R, Al-Nbaheen M, Kadalmani B, Aldahmash A, Ramesh T. Skin-derived multipotent stromal cells-An archrival for mesenchymal stem cells. Cell Tissue Res. 350(1), 1-12 (2012).
14. Huang HI, Chen SK, Ling QD, Chien CC, Liu HT, Chan SH. Multilineage differentiation potential of fibroblast-like stromal cells derived from human skin. Tissue Eng. Part A. 16(5), 1491-1501 (2010).
15. Lorenz K, Sicker M, Schmelzer E, et al. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp. Dermatol. 17(11), 925-932 (2008).
16. Li Y, Zhao Y, Cheng Z, et al. Mesenchymal stem cell-like cells from children foreskin inhibit the growth of SGC- 7901 gastric cancer cells. Exp. Mol. Pathol. 94(3), 430-437 (2013).
17. Park JR, Kim E, Yang J, et al. Isolation of human dermis derived mesenchymal stem cells using explants culture method: expansion and phenotypical characterization. Cell Tissue Bank. 16(2), 209-218 (2015).
18. Najar M, Raicevic G, André T, et al. Mesenchymal stromal cells from the foreskin: tissue isolation, cell characterization and immunobiological properties. Cytotherapy 18(3), 320-335 (2016).
19. Vishnubalaji R, Manikandan M, Al-Nbaheen M, Kadalmani B, Aldahmash A, Alajez NM. In vitro differentiation of human skin-derived multipotent stromal cells into putative endothelial-like cells. BMC Dev. Biol. 12, 7 (2012).
20. De Kock J, Najar M, Bolleyn J, et al. Mesoderm-derived stem cells: the link between the transcriptome and their differentiation potential. Stem Cells Dev. 21(18), 3309-3323 (2012).
21. Salehinejad P, Alitheen NB, Ali AM, et al. Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Whartons jelly. In Vitro Cell Dev. Biol. Anim. 48(2), 75-83 (2012).
22. Heymer A, Jany C, Kaufmann M. Isolation of keratinocytes and fibroblasts from human foreskin by one-step enzyme incubation using liberase research grade products. Biochemica. 2, 12-14 (2009).
23. Garg A, Houlihan DD, Aldridge V, et al. Non-enzymatic dissociation of human mesenchymal stromal cells improves chemokine-dependent migration and maintains immunosuppressive function. Cytotherapy 16(4), 545-559 (2014).
24. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15(11), 1009-1016 (2014).
25. Najar M, Rodrigues RM, Buyl K, et al. Proliferative and phenotypical characteristics of human adipose tissue-derived stem cells: comparison of Ficoll gradient centrifugation and red blood cell lysis buffer treatment purification methods. Cytotherapy 16(9), 1220-1228 (2014).
26. Lee WC, Shi H, Poon Z, et al. Multivariate biophysical markers predictive of mesenchymal stromal cell multipotency. Proc. Natl Acad. Sci. USA 111(42), E4409- E4418 (2014).
27. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci. Rep. 35(2), pii: e00191 (2015).
28. Kurt Yüksel M, TopçuoǦlu P, Kurdal M, Ilhan O. The clonogenic potential of hematopoietic stem cells and mesenchymal stromal cells in various hematologic diseases: a pilot study. Cytotherapy 12(1), 38-44 (2010).
29. Mamidi MK, Pal R, Mori NA, et al. Co-culture of mesenchymal-like stromal cells derived from human foreskin permits long term propagation and differentiation of human embryonic stem cells. J. Cell Biochem. 112(5), 1353-1363 (2011).
30. Melton D. Stemness: definitions, criteria, and standards. In: Essentials of Stem Cell Biology (3rd Edition). Lanza R, Atala A (Eds). Elsevier Academic Press, 7-17 (2014).
31. Tsai CC, Su PF, Huang YF, Yew TL, Hung SC. Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells. Mol. Cell. 47(2), 169-182 (2012).
32. Pierantozzi E, Gava B, Manini I, et al. Pluripotency regulators in human mesenchymal stem cells: expression of NANOG but not of OCT-4 and SOX-2. Stem Cells Dev. 20(5), 915-923 (2011).
33. Piccinato CA, Sertie AL, Torres N, Ferretti M, Antonioli E. High OCT4 and low p16 (INK4A) expressions determine in vitro lifespan of mesenchymal stem cells. Stem Cells Int. 2015, 369828 (2015).
34. Zhao G, Liu F, Lan S, et al. Large-scale expansion of Whartons jelly-derived mesenchymal stem cells on gelatin microbeads, with retention of self-renewal and multipotency characteristics and the capacity for enhancing skin wound healing. Stem Cell Res. Ther. 6(1), 38 (2015).
35. Ferretti C, Lucarini G, Andreoni C, et al. Human periosteal derived stem cell potential: the impact of age. Stem Cell Rev. 11(3), 487-500 (2015).
36. Liu Y, Wang S, Shi S. The role of recipient T cells in mesenchymal stem cell-based tissue regeneration. Int. J. Biochem. Cell Biol. 44(11), 2044-2050 (2012).
37. Zhang J, Li ZG, Si YM, Chen B, Meng J. The difference on the osteogenic differentiation between periodontal ligament stem cells and bone marrow mesenchymal stem cells under inflammatory microenviroments. Differentiation 88(4-5), 97-105 (2014).
38. Sullivan CB, Porter RM, Evans CH, et al. TNFα and IL-1β influence the differentiation and migration of murine MSCs independently of the NF-?B pathway. Stem Cell Res. Ther. 5(4), 104 (2014).
39. Lacey DC, Simmons PJ, Graves SE, Hamilton JA. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage 17(6), 735-742 (2009).
40. Sun Z, Han Q, Zhu Y, et al. NANOG has a role in mesenchymal stem cells immunomodulatory effect. Stem Cells Dev. 20(9), 1521-1528 (2011).
41. Halleux C, Sottile V, Gasser JA, Seuwen K. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J. Musculoskelet. Neuronal Interact. 2(1), 71-76 (2001).
42. Li L, Fukunaga-Kalabis M, Yu H, et al. Human dermal stem cells differentiate into functional epidermal melanocytes. J. Cell Sci. 123(Pt 6), 853-860 (2010).
43. Vaculik C, Schuster C, Bauer W, et al. Human dermis harbors distinct mesenchymal stromal cell subsets. J. Invest. Dermatol. 132(3 Pt 1), 563-574 (2012).
44. Orbay H, Tobita M, Mizuno H. Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. Stem Cells Int. 2012, 461718 (2012).
45. Zhong J, Hu N, Xiong X, Lei Q, Li L. A novel promising therapy for skin aging: dermal multipotent stem cells against photoaged skin by activation of TGF-β/Smad and p38 MAPK signaling pathway. Med. Hypotheses. 76(3), 343-346 (2011).
46. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 17, 187-194 (2003).
47. Pevsner-Fischer M, Zipori D. Environmental signals regulating mesenchymal progenitor cell growth and differentiation. In: Regulatory Networks in Stem Cells. Rajasekhar VK, Vemuri MC (Eds). Humana Press, NY, USA, 175-184 (2009).
48. Dugast AS, Vanhove B. Immune regulation by non-lymphoid cells in transplantation. Clin. Exp. Immunol. 156(1), 25-34 (2009).
49. Tasso R, Pennesi G. When stem cells meet immunoregulation. Int. Immunopharmacol. 9(5), 596-598 (2009).
50. Wada N, Bartold PM, Gronthos S. Human foreskin fibroblasts exert immunomodulatory properties by a different mechanism to bone marrow stromal/stem cells. Stem Cells Dev. 20(4), 647-659 (2011).
51. Pfisterer K, Lipnik KM, Hofer E, Elbe-Bürger A. CD90(+) human dermal stromal cells are potent inducers of FoxP3(+) regulatory T cells. J. Invest. Dermatol. 135(1), 130-141 (2015).
52. Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 15(6), 641-648 (2013).
53. Suga H, Matsumoto D, Eto H, et al. Functional implications of CD34 expression in human adipose-derived stem/.progenitor cells. Stem Cells Dev. 18(8), 1201-1210 (2009).
54. Campioni D, Rizzo R, Stignani M, et al. A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry B Clin. Cytom. 76(3), 225-230 (2009).
55. Wiesmann A, Bühring HJ, Mentrup C, Wiesmann HP. Decreased CD90 expression in human mesenchymal stem cells by applying mechanical stimulation. Head Face Med. 2, 8 (2006).
56. Jin HJ, Park SK, Oh W, Yang YS, Kim SW, Choi SJ. Down-regulation of CD105 is associated with multi-lineage differentiation in human umbilical cord blood-derived mesenchymal stem cells. Biochem. Biophys. Res. Commun. 381(4), 676-681 (2009).
57. Mafi P, Hindocha S, Mafi R, Griffin M, Khan WS. Adult mesenchymal stem cells and cell surface characterization - A systematic review of the literature. Open Orthop. J. 5(Suppl. 2), 253-260 (2011).
58. Al-Nbaheen M, Vishnubalaji R, Ali D, et al. Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev. 9(1), 32-43 (2013).
59. Autoimmune Diseases and the Promise of Stem Cell-Based Therapies. In Stem Cell Information. National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, USA 2009. http://stemcells.nih.gov/info/scireport/pages/chapter6.aspx
60. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31(10), 890-896 (2003).
61. Romieu-Mourez R, François M, Boivin MN, Stagg J, Galipeau J. Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J. Immunol. 179(3), 1549-1558 (2007).
62. de la Garza-Rodea AS, Verweij MC, Boersma H, et al. Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants. PLoS ONE 6(1), e14493 (2011).
63. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109(3), 295-299 (2002).
64. Briones J, Novelli S, Sierra J. T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications. Bone Marrow Res. 2011, 976793 (2011).
65. Wiendl H, Mitsdoerffer M, Schneider D, et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J. 17(13), 1892-1894 (2003).
66. Castro-Manrreza ME, Mayani H, Monroy-García A, et al. Human mesenchymal stromal cells from adult and neonatal sources: a comparative in vitro analysis of their immunosuppressive properties against T cells. Stem Cells Dev. 23(11), 1217-1232 (2014).
67. Brooke G, Tong H, Levesque JP, Atkinson K. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev. 17(5), 929-940 (2008).
68. Pachón-Peña G, Yu G, Tucker A, et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J. Cell Physiol. 226(3), 843-851 (2011).
69. Yamashita Y, Kouro T, Miyake K, et al. Participation of intercellular adhesion molecule-2 (CD102) in B lymphopoiesis. Immunol. Lett. 120(1-2), 79-86 (2008).
70. Payne NL, Sun G, McDonald C, et al. Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant. 22(8), 1409-1425 (2013).
71. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells. 24(4), 1030-1041 (2006).
72. Najar M, Raicevic G, Id Boufker H, et al. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp. Hematol. 38(10), 922-932 (2010).
73. Najar M, Raicevic G, Fayyad-Kazan H, et al. Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the T cell response: the importance of the IL-10/CD210 axis. Stem Cell Rev. 11(3), 442-452 (2015).
74. Khosrotehrani K. Mesenchymal stem cell therapy in skin: why and what for?. Exp. Dermatol. 22(5), 307-310 (2013).
75. Wolbank S, Peterbauer A, Fahrner M, et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng. 13(6), 1173-1183 (2007).
76. Najar M, Raicevic G, Fayyad-Kazan H, et al. Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration. Int. Immunopharmacol. 15(4), 693-702 (2013).
77. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J. Immunol. Res. 2015, 394917 (2015).
78. Hoogduijn MJ. Are mesenchymal stromal cells immune cells?. Arthritis Res. Ther. 17(1), 88 (2015).
79. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305(1), 33-41 (2005).
80. Meisel R, Brockers S, Heseler K, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2, 3-dioxygenase. Leukemia 25(4), 648-654 (2011).
81. Munn DH, Mellor AL. Indoleamine 2, 3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34(3), 137-143 (2013).
82. Gieseke F, Schütt B, Viebahn S, et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood. 110(6), 2197-2200 (2007).
83. Chinnadurai R, Copland IB, Patel SR, Galipeau J. IDO-independent suppression of T cell effector function by IFN- γ-licensed human mesenchymal stromal cells. J. Immunol. 192(4), 1491-1501 (2014).
84. Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin. Exp. Immunol. 171(1), 1-7 (2013).
85. Sundin M, Darcy P, Johansson CC, et al. Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?. J. Immunother. 34(4), 336-342 (2011).
86. Lee JJ, Jeong HJ, Kim MK, et al. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. Purinergic Signal. 10(2), 357-365 (2014).
87. Chabannes D, Hill M, Merieau E, et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110(10), 3691-3694 (2007).
88. Patel SR, Copland IB, Garcia MA, Metz R, Galipeau J. Human mesenchymal stromal cells suppress T-cell proliferation independent of heme oxygenase-1. Cytotherapy 17(4), 382-391 (2015).
89. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25 Highforkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156(1), 149-160 (2009).
90. Rizzo R. Immunosupressive properties of HLA-G molecules produced by mesenchymal stromal cells. J. Transplant Technol. Res. 3, e127 (2013).
91. Kyurkchiev D, Bochev I, Ivanova-Todorova E, et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J. Stem Cells 6(5), 552-570 (2014).
92. Hsu WT, Lin CH, Chiang BL, Jui HY, Wu KK, Lee CM. Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-γ+CD4+ regulatory T cells to control transplant arteriosclerosis. J. Immunol. 190(5), 2372-2380 (2013).
93. Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int. J. Oncol. 38(2), 385-390 (2011).
94. Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol. 253(1-2), 16-22 (2008).
95. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10), 3838-3843 (2002).
96. Nasef A, Chapel A, Mazurier C, et al. Identification of IL- 10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 13(4-5), 217-226 (2007).
97. Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schäfer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 11, 146 (2013).
98. Putoczki T, Ernst M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88(6), 1109-1117 (2010).
99. Hjertner O, Torgersen ML, Seidel C, et al. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-Associated osteolytic bone disease. Blood 94(11), 3883-3888 (1999).
100. Goff JP, Shields DS, Petersen BE, Zajac VF, Michalopoulos GK, Greenberger JS. Synergistic effects of hepatocyte growth factor on human cord blood CD34+ progenitor cells are the result of c-met receptor expression. Stem Cells 14(5), 592-602 (1996).
101. Amorin B, Alegretti AP, Valim V, et al. Mesenchymal stem cell therapy and acute graft-versus-host disease: a review. Hum. Cell. 27(4), 137-150 (2014).
102. Auletta JJ, Eid SK, Wuttisarnwattana P, et al. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells. 33(2), 601-614 (2015).
103. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102(1), 115-123 (1998).
104. Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 104(3), 317-325 (1999).
105. Kizil C, Kyritsis N, Brand M. Effects of inflammation on stem cells: together they strive?. EMBO Rep. 16(4), 416-426 (2015).
106. Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109(4), 1422-1432 (2007).
107. Raicevic G, Rouas R, Najar M, et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum. Immunol. 71(3), 235-244 (2010).
108. Zhukareva V, Obrocka M, Houle JD, Fischer I, Neuhuber B. Secretion profile of human bone marrow stromal cells: donor variability and response to inflammatory stimuli. Cytokine. 50(3), 317-321 (2010).
109. Crop MJ, Baan CC, Korevaar SS, et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin. Exp. Immunol. 162(3), 474-486 (2010).
110. Hänel KH, Cornelissen C, Lüscher B, Baron JM. Cytokines and the skin barrier. Int. J. Mol. Sci. 14(4), 6720-6745 (2013).
111. Raicevic G, Najar M, Stamatopoulos B, et al. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol. 270(2), 207-216 (2011).
112. Iram N, Mildner M, Prior M, et al. Age-related changes in expression and function of Toll-like receptors in human skin. Development 139(22), 4210-4219 (2012).